Eton Pharmaceuticals, Inc. Total Assets
Eton Pharmaceuticals, Inc. (ETON) had Total Assets of $115.81 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-08-13
- 2026-06-30: Assets $115.81M.
- 2026-03-31: Assets $97.71M.
- 2025-12-31: Assets $92.11M.
- 2025-09-30: Assets $104.51M.
| Period end | Assets |
|---|---|
| 2026-06-30 | $115.81M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $97.71M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $92.11M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $104.51M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $101.68M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $84.03M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $76.12M 10-K · filed 2026-03-19 |
| 2024-09-30 | $35.84M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $31.82M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $30.79M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $31.74M 10-K · filed 2025-03-18 |
| 2023-09-30 | $31.53M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $30.93M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $23.93M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $25.03M 10-K · filed 2024-03-14 |
| 2022-09-30 | $21.52M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $23.05M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $23.20M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $27.46M 10-K · filed 2023-03-16 |
| 2021-09-30 | $26.61M 10-Q · filed 2021-11-16 |
| 2021-06-30 | $29.91M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $31.19M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $26.32M 10-K · filed 2022-03-16 |
| 2020-09-30 | $11.39M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $14.56M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $17.24M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $17.07M 10-K · filed 2021-03-16 |
| 2019-09-30 | $13.51M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $18.24M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $23.02M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $28.33M 10-K · filed 2020-03-05 |
| 2018-09-30 | $7.53M 10-Q · filed 2018-12-20 |
| 2017-12-31 | $13.44M 10-K · filed 2019-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |